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Summary 
Previous work has indicated a crucial role for the extracellular cysteine proteinase of Streptococ- 
cus pyogenes  in the pathogenicity and virulence of this important human pathogen.  Here we 
find that the purified streptococcal cysteine proteinase releases  biologically active kinins from 
their purified precursor protein, H-kininogen, in vitro, and from kininogens present in the hu- 
man plasma,  ex vivo. Kinin liberation in the plasma  is due to the direct action of the strepto- 
coccal proteinase on the kininogens, and does not involve the previous activation of plasma 
prekallikrein,  the  physiological  plasma  kininogenase.  Judged  from  the  amount  of released 
plasma  kinins  the bacterial proteinase is highly efficient in its action. This is also  the case  in 
vivo. Injection of the purified cysteine proteinase into the peritoneal cavity of mice resulted in 
a progressive cleavage of  plasma kininogens and the concomitant release ofkinins over a period 
of 5 h. No kininogen degradation was seen in mice when the cysteine proteinase was inacti- 
vated by the specific inhibitor, Z-Leu-Val-Gly-CHN2, before administration.  Intraperitoneal 
administration into mice of living S.  pyogenes  bacteria producing the  cysteine proteinase in- 
duced a rapid breakdown of endogenous plasma kininogens and release of kinins.  Kinins are 
hypotensive, they increase vascular permeability, contract smooth muscle, and induce fever and 
pain. The release ofkinins by the cysteine proteinase orS. pyogenes could therefore represent an 
important and previously unknown virulence mechanism in S, pyogenes infections. 
S 
treptococcus pyogenes causes suppurative infections such as 
acute  pharyngitis,  impetigo,  and  erysipelas  whereas 
glomerulonephritis and rheumatic  fever are clinically im- 
portant sequelae following these acute infections. Since the 
late 1980's an increase of toxic and severe S. pyogenes infec- 
tions has been reported worldwide (1), and observations in 
various laboratories have suggested that an extraceilular cys- 
teine proteinase produced by S. pyogenes may contribute to 
this hyperacute and often lethal toxic shock-like syndrome. 
The  streptococcal  cysteine  proteinase  (SCP) 1 was  the 
first prokaryotic cysteine proteinase to be isolated and this 
early work  also  demonstrated that  the  enzyme has  profi- 
brinolytic  activity  (2).  More  recently,  Gerlach  et  al.  (3) 
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found that SCP is identical to erythrogenic toxin B, one of 
the  classical toxins of S.  pyogenes.  Experimental infections 
in mice indicated that SCP is an important virulence deter- 
minant  (4,  5)  and patients with fatal  S. pyogenes  infections 
have lower antibody titers to SCP in the acute phase than 
patients with less severe infections (6).  Moreover, the en- 
zyme activates human interleukin-l[3 (7), a major cytokine 
mediating inflammation and shock. SCP also degrades hu- 
man extracellular matrix proteins (8)  and releases  biologi- 
cally active fragments  of surface proteins  expressed by S. 
pyogenes  (9).  One  of these  fragments,  derived  from  the 
streptococcal C5a peptidase (10), blocks the recruitment of 
leukocytes to the site  of infection (9). SCP is also thought 
to inhibit cell migration by the proteolytic cleavage of the 
urokinase receptor exposed on the surface of mononuclear 
phagocytes (11). An extracellular product of S. pyogenes re- 
ferred to as nephritis-associated protein, is identical to the 
inactive zymogen form of SCP (12) that is rapidly activated 
upon injection into the mouse peritoneum (Cooney, Liu, 
and Bj6rck, in preparation).  Combined,  these various ex- 
perimental data suggest an important role for SCP in viru- 
lence. 
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ate vasodilatation, spasm, pain, fever, and edema due to in- 
creased vascular permeability (13). Under physiological con- 
ditions, the kinins are released from their large multifunctional 
precursor  proteins,  high  molecular  weight  (H-)kininogen 
and  low-molecular-weight  (L-)kininogen, by the  proteo- 
lytic action of the kallikreins (14,  15), see Fig.  1. In a recent 
study,  a  majority of S.  pyogenes  strains was  found  to  bind 
kininogens with high affinity and specificity (16) and a goal 
of the  present work  was  therefore  to  investigate whether 
SCP can liberate kinins from the kininogens in vitro and in 
vivo.  The  release  of highly potent pro-inflammatory host 
peptides such as kinins may explain in part the hyperacute 
and severe symptoms of the toxic shock syndrome. Our re- 
sults demonstrate that SCP indeed has this capacity. 
Materials  and  Methods 
Bacterial Strains.  S.  pyogenes  strains  AP1  (40/58)  and  AP74 
(30/50)  are from  the  World Health  Organisation Collaborating 
Centre for References and Research  on Streptococci, Institute of 
Hygiene and Epidemiology (Prague, Czech Republic). 
Sources o[ Proteins and Antibodies.  H-kininogen was isolated  from 
human plasma (17)  with modifications previously described (18). 
The  streptococcal  cysteine proteinase  (SCP)  was  purified from 
the culture medium of strain AP1  (9).  The AP1 supernatant was 
subjected to  ammonium sulfate precipitation (80%)  followed by 
fractionation  on  S-Sepharose  in  a  buffer gradient  (5-250  mM 
MES, pH 6.0). The zymogen was further purified by gel filtration 
on Sephadex G-200 (9).  Monoclonal antibodies to human kini- 
nogens (HKH 15 and HKL 9) were produced in mice (19), poly- 
clonal antiserum (AS88)  to  human H-kininogen in sheep  (20), 
and polyclonal antiserum against the streptococcal cysteine pro- 
teinase were  raised in rabbits.  Antiserum to bradykinin (cx-BK, 
AS348)  was  produced  in a  rabbit by previous  coupling of the 
cognate  peptides  to  keyhole limpet hemocyanin (KLH)  via the 
carbodiimide method (2l). Peroxidase-con3ugated goat anti-rab- 
bit,  goat  anti-mouse  (Bio-Rad,  IKichmond,  CA),  or  donkey 
anti-sheep imnmnoglobulins (ICN,  Aurora,  OH)  were  used as 
secondary  antibodies.  The  Z-Leu-VaI-Gly-CHN  2  peptide  has 
been described (4). 
Ch'ava,  ge qflH-kininoge, by SCP.  H-kininogen (0.5 mg/ml) was 
incubated  at  37~  with  SCP  in  10  mM  NaH2PO4,  10  mM 
Na2HPO4, 0.15 M  NaC1, pH 7.4 (PBS) containing l  mM dithio- 
threitol (DTT); the molar ratio ofsubstrate over enzyme was 100: 
1 or  l: 1. Aliquots (8/xl) of the reaction mixture were removed at 
the indicated time points, and the reaction stopped by adding 10 
txl of a 2% (wt/vol) sodium dodecyl sulfate (SDS)  sample buffer 
(22)  containing 5%  (vol/vol) 2-mercaptoethanol, and boiling at 
95~  Alternatively the  reaction was  stopped  by addition of 10 
IxM  (final concentration) of N-[2\L(L-3-transcarboxyoxiran-2-car  - 
bonyl)-L-leucyl]-agmatin (E-64). 
Cleava2e qf Plasma Prekallikrein  by SCP.  Plasma  prekallikrein 
(16 Ixg) was incubated with 0.05-0.5 Ixg of SCP in 100 txl of PBS 
containing 1 lnM I)TT at 37~  for 60 nfin; the molar ratio was 
10:1 to  100:1. The reaction was stopped by adding 10 p,1 of SDS 
sample  buffer containing 5%  2-mercaptoethanol and boiling at 
95~  alternatively E-64  was  added  to  a  final concentration of 
10 b~M. 
Prekallikrein Activation.  Plasma prekallikrein (4 ~g) was  incu- 
bated for 1 h with 0.012 I~g factor XIIa in 40 la,1 of PBS, or for 3 h 
with varying amounts (0.12-0.012  btg) of SCP at 37~  To test 
the activity of the generated proteinase, kallikrein was added  to 
200  btl  of a  0.6  mM  solution of S-2302  (H-D-Pro-Phe-Arg- 
p-nitro-anilide;  Haemochrom  Diagnostica,  Essen,  Germany)  in 
0.15 M  Tris-HC1, pH 8.3. The substrate hydrolysis was measured at 
405 nm. 
Cleavage of Plasma Proteins b  l, SCP.  100  t*1 of human plasma 
was incubated with 3.2 I.Lg  of SCP dissolved in 100 I*1 PBS,  10 mM 
DTT, pH 7.4, at 37~  The reaction was stopped by the addition 
of 100 I*1 of SDS sample buffer containing 5% 2-mercaptoethanol 
(22) and boiling at 95~  for 5 rain. 
SDS-polyacrylamide  Gel Elearophoresis (PA GEL  Proteins were 
separated by 10 or 12.5% (wt/vol) polyacrylanfide gel electrophore- 
sis in the presence of 1% (wt/vol) SDS  (22).  Standard molecular 
weight markers were from Sigma Chem. Co (St. Louis, MO). 
PVestem Blotti~lg and lmmunoprintin6  Proteins were resolved by 
SDS-PAGE and transferred onto nitrocellulose membranes for 30 
rain at  100 mA (23), The membranes were blocked with 50 mM 
KH2PO  4, 0.2 M  NaC1, pH 7.4, containing 5% (wt/vol) dry milk 
powder and 0.05%  (wt/vol)  Tween 20.  hnnmnoprinting of the 
transferred proteins was  done  according to  Towbin et  al.  (24). 
The first antibody was diluted 1:1000 in the blocking buffer (see 
above). Bound antibody was detected by a peroxidase-conjugated 
secondary antibody against sheep, rabbit or mouse immunoglob- 
ulin followed by the chemiluminescence detection method. 
Ca  2+ Rek,  ase  from Intracellular Stores.  Human  foreskin  fibroblasts 
(HF-15) on 10-ram diameter glass coverslips were grown to con- 
fluency  in  Dulbecco's  modified  Eagle's  medium  supplemented 
with 10% (v/v) fetal calf serum (25).  The cells were washed twice 
with minimum essential medium buffered with 20 mM Na +-Hepes, 
pH 7.4 (buffer A; without vitamins, and CX-D-glucose added im- 
mediately before use). The cells were loaded for 30 rain at 37~ 
with  2  FxM  1-[2-(5-carboxyoxazol-2-yl)-6-aminobenzofuran-5- 
oxyJ-2-(2",nnino-5 "methylphenoxy)-ethane-N,N,N',N'-tetra  ace- 
tic acid,  pentaacetoxymethylester (fura-2/AM; Calbiochem Nova- 
biochem, San Diego, CA) in buffer A containing l).04%  (wt/vol) 
of the  nonionic detergent  pluronic F-127  (Calbiochem  Nova- 
biochem) (25).  The cells were washed twice with buffer A. The 
Hitachi F4500 fluorescence photometer was  employed with the 
H-kininogen 
D1 
L-kininogen 
D1 
D2  D3  D/,  D5 H  D6 H 
D2  D3  D/.  D5 L 
Figure  1.  Gross  structure ofmanunalian kininogens. H-kininogen and 
L-kininogen share their  heavy chain domains, l)1  to  I)4,  and differ m 
their light chain domains, I)5H/D6 n and DSL, respectively. Domains 1)1 
to 1)3 are of cystatm-like structure; domain I)2 inhibits calpam and pa- 
pain-like  cysteme proteinases whereas I)3 inhibits only papain-like en- 
zymes and exposes a cell binding site. The kinin segment is located in do- 
main  1)4. Domain  I)5~  of H-kininogen exposes a  high-affinity  cell 
binding site which is also used by streptococcal M protein, l)omain 1)6  H 
contains the overlapping binding sites for prekallikrein and factor XI. The 
fhnction of D5 L of L-kininogen is unknown. Proteinase-sensitive regions 
flanking the kmin segnnent are indicated by pairs of solid arrowheads. 
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and the emission wavelength set at 510  nm. To induce the Ca  2+ 
release,  2  txg  H-kininogen  or  proteolytic  cleavage  products 
thereof in 20  Ixl of reaction buffer was added 60 s after starting 
the  measurement.  The  release of Ca  2+  from  intracellular stores 
was followed for 300  s; the free intercellular Ca  2+  concentration 
was  calculated from  the  ratio of 340  nm/380  nm  as described 
(25). 
Determination of Kinin Concentrations in Plasma.  To  measure  the 
SCP-induced kinin release 100  Ixl of plasma was incubated with 
3.2 I~g of SCP in 100  ~1 PBS containing 10 mM DTT.  Samples 
(10 Ixl each) were removed after 0, 30, 60, 90, and 120 min. The 
reaction was stopped by adding E-64 to a final concentration of 
10 txM.  For control 100 ~l of human plasma was incubated with 
buffer in the absence of SCP. The samples were diluted 1:100  in 
distilled water. Aliquots (100  Ixl each) were mixed with 20 txl of 
20%  (wt/vol) trichloroacetic acid and centrifuged at  1,500 g  for 
10 rain. The kinin concentrations in the reaction mixtures were 
quantitated by the Markit-A kit (Dainippon Pharmaceutical Co., 
Osaka, Japan)  as described (26).  Briefly, aliquots of the superna- 
tant (75 ~1 each) were mixed with 75  Ftl of the kit buffer, and ap- 
plied to  the  wells  (100  ~1  each)  of microtiter plates that  were 
coated  with  capture  antibodies to  rabbit  immunoglobulin  fol- 
lowed by specific anti-bradykinin antibodies. After 1 h of incuba- 
tion, the peroxidase-labeled  bradykinin probe was applied and in- 
cubated for 1 h. The amount of bound peroxidase was visualized 
by the substrate solution, 0.1% (wt/vol) diammonium-2,2'-azinobis- 
(3-ethyl-2,3-dihydrobenzthiazoline)-6-sulfonate  (ABTS), 0.012% 
(vol/vol) H202  in  100  rn/Vl citric acid,  100 mM NaH2PO4,  pH 
4.5, for 3() min. The change of absorbance was  read at 405  nm. 
The reference standards were prepared according to the manufac- 
turer's instructions. 
Animal Experiments.  S.  pyogenes of strains  AP1  and  AP74 
were grown in Todd-Hewitt broth (Difco, Detroit, MI) at 37~ 
for 16  h, and harvested by centrifugation at 3,000 g for 20 rain. 
The bacteria were washed twice with PBS,  and resuspended in 
PBS to 3  ￿  10  s cel/s/ml. 1 ml of living bacteria was injected in- 
traperitoneally into  outbred NMRI  mice.  Plasma samples were 
taken 10 h  after injection. Alternatively, mice were injected with 
the purified non-activated SCP (0.1-0.5 rag), and plasma samples 
were taken 60,  150, and 300 rain after injection. For inactivation 
of SCP,  0.5  mg of the enzyme was mixed with 0.2 mg Z-Leu- 
Val-Gly-CHN2 prior to  injection.  To  monitor the  cleavage of 
kininogen,  l  txl of plasma was run  on SDS-PAGE followed by 
Western blotting with antibodies against bradykinin (ec-BK). 
Quantification of SCP in Mouse Plasma.  One  Ixl of plasma sam- 
ples  from  mice injected with  SCP was run  on  SDS-PAGE and 
transferred onto nitrocellulose. The enzyme was visualized by im- 
nmnostaining  using  antibodies  against  SCP.  To  obtain  senti- 
quantitative estimates of the SCP amounts in plasma samples, pu- 
rified SCP (3-100 ng) was processed as described above and used 
as a standard. 
Results 
Streptococcal Cysteine Proteinase  Is Not Inhibited by H-Kinin- 
ogen.  The  streptococcal cysteine proteinase  (SCP)  cleaves 
surface proteins of S. pyogenes strain AP1  (9). One of its tar- 
get  structures,  the  streptococcal  M1  protein,  specifically 
binds kininogens (16) the major cysteine proteinase inhibi- 
tors  of human  plasma.  These  observations  prompted  the 
notion that kininogens bound to the bacterial surface might 
regulate  the  proteolytic  activity  of  SCP.  We  therefore 
tested  the  effect  of H-kininogen  on  the  hydrolysis  of a 
chromogenic  peptide  substrate  by  SCP.  Unexpectedly, 
H-kininogen had no inhibitory effect on the amidolytic ac- 
tivity of SCP  (not shown),  whereas  the  synthetic cysteine 
proteinase inhibitor E-64,  efficiently blocked the  SCP  ac- 
tivity in  the  same assay. We  therefore  asked the  question 
whether H-kininogen serves as a substrate--rather than an 
inhibitor for SCP. 
SCP Degrades H-Kininogen.  When we analyzed the re- 
action  mixture  of H-kininogen  and  SCP  by  SDS-PAGE 
we found that SCP rapidly and almost completely degraded 
H-kininogen (Fig. 2). To follow the breakdown of H-kinin- 
ogen  by SCP,  and  to  identify potential cleavage products 
such as the biologically active kinin peptides, we employed 
Western blotting and immunoprinting of the reaction mix- 
tures.  We used polyclonal antibodies directed to the kinin 
sequence of nine residues located in domain D4 of H-kinin- 
ogen,  and monoclonal antibodies to the flanking domains, 
D3  and D5 H (see Fig. 1). Fig. 3  shows three rephcas of the 
SCP  cleavage products of H-kininogen separated by SDS- 
PAGE  and  immunopfinted  by  a  rnonoclonal  antibody 
against the COOH-terminal part of domain D3  (HKH  15; 
Fig.  3  A), by a  polyclonal antibody to  bradykinin  (cr 
Fig.  3  B),  and by a  monoclonal antibody recognizing the 
NH2-terminal part of domain D5,  (HKL 9; Fig. 3  C), re- 
spectively. The  immunoprints  reveal a  complex pattern of 
kininogen  degradation products.  The  native  H-kininogen 
of 105  kD  is rapidly cleaved into  fragments  of 60-75  kD 
containing the D3  epitope (A), and into fragments of 45- 
70 kD  comprising the D5H  epitope (C).  initially the kinin 
epitope which is rapidly lost from the native kininogen of 
105  kD,  remains  associated with  a  band  of 60  kD  that  is 
also recognized by the  anti-heavy chain  antibody  (A) but 
not by the anti-light chain antibody (C). This would indi- 
cate that the initial cleavage by SCP occurs at site(s) located 
distally of the bradykinin moiety, and therefore the brady- 
kinin sequence  remains attached to  the  heavy chain.  Fur- 
ther proteolysis by SCP breaks down the kininogen heavy 
chain,  most  probably  into  its  constituting  domains  (note 
that the various domains D1  through D3  of the kininogen 
Figure 2.  Cleavage  of H-kinin- 
ogen  by  the  streptococcal cys- 
teine proteinase (SCP). H-kinin- 
ogen (30 Ixg)  was incubated with 
0.07 ~g of SCP  (molar ratio of 
100:1). After 15 nfin (lane 2), 30 
rain  (lane 3),  60  rain  (lane 4), 
120  min  (lane 5),  or  180  rain 
(lane 6) of incubation aliquots of 
the reacuon mixture (4 Ixg pro- 
tein each) were separated by SDS-PAGE (10% vol/vol) under reducing 
conditions, followed by staining with Coomassie Brilliant Blue. For con- 
trol H-kininogen incubated for 180 rain in the absence of SCP was ap- 
plied (lane I). Note that a small amount of the purified H-kininogen ex- 
ists in its kinin-free two chain form. Standard molecular marker proteins 
were run simultaneously (not shown); their relative positions are indi- 
cated on the left. 
667  Herwald et al. Figure  3.  lmmunoprint  analysis  of H-kininogen  cleavage  products. 
Aliquots from  the  reaction  mixture  of H-kininogen  (30  t,  tg)  and  SCP 
(0.07 >g)  were removed after 15  min (lane 2),  30 rain  (lane 3),  60 rain 
(lane  4),  120 rain  (lane  ~,  or  180 min (lane  6)  and separated by SDS- 
PAGE followed by electrotransfer onto nitrocellulose. For control nanve 
H-kininogen incubated for  180 rain in  the absence of SCP  (1)  was ap- 
plied. Blots were incubated with HKH 15 antibody (A), cl-BK antibodies 
(B),  or HKL 9 antibody (C). Bound antibodies were visualized with per- 
oxidase  labeled  anti-mouse  or  anti-rabbit  immunoglobulins  and  the 
chemiluminescence technique.  The  relative  locations of the  antibodies 
target  epitopes are  indicated  on  the bottom;  the domain designation is 
that of Fig.  1. Note that cl-BK shows a higher affinity for kininogen frag- 
ments rather than for the uncleaved H-kininogen. 
heavy chain are separated by protease-sensitive regions that 
expose the primary attack sites  for many proteinases; 27). 
Accordingly, a prominent band of ~23  kD appears at the 
later stages  of proteolysis representing domain  D3  (B). A 
fraction of D3 still contains the COOH-terminal extension 
of bradykinin  (B,  lanes  3  and  4)  that is lost as proteolysis 
proceeds (~>120 min).  No shift in the apparent molecular 
mass  of the D3  fragment is  obvious (see A,  lanes  3  to  6) 
suggesting that only a minor peptide such as bradykinin is 
removed  from  the  23-kD  fragment.  Nevertheless,  we 
sought to determine whether SCP releases authentic kinins 
from H-kininogen. 
H-kininogen  Cleavage  Products  Release Intracellular  Ca  2.  i, 
Human Fibroblasts.  To  demonstrate  the  presence  of bio- 
logically active  kinins  in  the  proteolytic digests  we  em- 
ployed the fura-2/AM assay. This test system monitors the 
bradykinin B2 receptor-mediated release of Ca  2+ from in- 
tracellular stores of human foreskin fibroblasts  (25). Purified 
H-kininogen did not induce a Ca  2+ release from human fi- 
broblasts  (Fig.  4  A);  hence  the  starting  product  did  not 
contain appreciable amounts ofkinins. In contrast the reac- 
tions  mixtures from the  incubation  of H-kininogen  with 
SCP  for 60  min  (C)  or  120  min  (D)  induced significant 
Ca  2+ signals thus indicating the presence of biologically ac- 
tive kinins. The specificity of the assay was probed by pre- 
incubating the cells with the potent B2 receptor antagonist, 
HOE140, which completely abrogated the Ca  2+ signal  in- 
duced  by  the  application  of  the  kininogen  breakdown 
products  (data  not shown).  H-kininogen which had been 
incubated for 120 min in the absence of SCP induced no 
Ca  2+ signal  (data  not shown); hence the kinin release  was 
not  due  to  a  contaminating kininogenase  associated  with 
the  starting  material.  Together  these  results  demonstrate 
that SCP releases biologically active kinins from H-kininogen. 
SCP Cleaves H-Kininogen  in Plasma.  To test whether SCP 
cleaves  H-kininogen in its physiological environment, the 
streptococcal enzyme was  added  to  plasma.  After varying 
time points, aliquots were removed from the reaction mix- 
ture and subjected to Western blot analyses.  Highty specific 
polyclonal antibodies to native H-kininogen (AS 88) and to 
bradykinin (oL-BK) were applied to identify the kininogen 
cleavage products in the complex plasma  mixture. Fig.  5 A 
demonstrates that the endogenous H-kininogen present in 
human plasma is partially degraded after 15 min, and almost 
completely split after 30 min of incubation with SCP. Be- 
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Figure  4.  Ca  2+  release  from 
mtracellular  stores  induced  by 
H-kminogen  cleavage  products. 
Confluent  human  fibroblasts 
loaded  with  fura-2  were  incu- 
bated  with  untreated  H-kinin- 
ogen  (A),  and  H-kininogen 
cleaved by SCP  for 30 rain  (B), 
60  rain  (C),  or  120  mm  (D)  at 
37~  The intracellular Ca  2~  re+ 
lease was measured as the ratio of 
fluorescence at excitation  wave- 
lengths os 340  nm and 380  nm+ 
respectively. 
668  Streptococcal  Cysteine Proteinase Releases Kinins Figure  5.  H-kininogen  cleavage in  plasma.  Human  plasma  (100  I*1) 
was incubated with 3.2 Dg of SCP. Samples were taken after 15 rain (lane 
2), 30 min (lane 3), 45 rain (lane 4), 60 min (lane 5), or 90 rain (lane  6) of 
incubation and separated by SDS-PAGE followed by the transfer of the 
proteins onto nitrocellulose and immunostaining by antibodies against na- 
tive H-kininogen (AS88; A) or to BK (cx-BK;/3).  For control, plasma was 
incubated in the absence of SCP for 90 rain (lane  I). The relative posi- 
tions of the human plasma kininogens are marked on the right. 
cause the antiserum (AS88)  is primarily directed to immu- 
nodominant epitopes of the H-kininogen light chain (20) it 
poorly  cross-reacts  with  L-kininogen  which  is  seen  as  a 
faint band of 66 kD  (A, lane  1; see  B, lane  1). The cx-BK 
antibodies reacted weakly with the native forms of H-kini- 
nogen and L-kininogen, respectively (B, lane  1). After 15 
rain  of incubation a  strong immunoreactivity at 66 kD  is 
visible which likely corresponds to a kinin-containing frag- 
ment representing the kininogen heavy chain including the 
bradykinin epitope (note that the cleavage of a scissile bond 
flanking  the  kinin  segment  results  in  a  major  conforma- 
tional change  of the kininogen molecule and a  concomi- 
tant exposure of the bradykinin epitope), Under the condi- 
tions of our experiment SDS-PAGE does not resolve the 
putative  fragment  and  L-kininogen  because  the  proteins 
differ only by 36 residues. After 15 rain of SCP proteolysis 
a smaller fragment of ~60  kD  is recognized by the  anti- 
bradykinin  antibodies  (B,  lane  2).  This  latter  fragment 
which peaks at 30 rain (B, lane 3) and fades away after pro- 
longed incubation is likely to represent a degradation prod- 
uct of the kininogen heavy chain with bradykinin still at- 
tached to  its  carboxy terminus.  Unlike  the  former band, 
i.e.,  heavy chain  comprising  the  bradykinin  epitope,  the 
latter band,  presenting a putative heavy chain degradation 
product,  is  not  observed  when  kininogen  is  split  by  its 
physiological  processing  enzyme,  plasma  kallikrein  (20). 
The  prominent  45-kD  band  that  occurs  throughout  the 
entire  incubation  procedure  (Fig.  5  B)  is  likely  to  be  a 
staining  artefact  of the  cx-BK antibodies  when  plasma  is 
used;  we  did not observe such an immunoreactivity with 
purified H-kininogen (see Fig. 3). We could not detect any 
significant kininogen degradation in plasma that was incu- 
bated in  the  absence of SCP  (data  not shown).  Together 
these data suggest that SCP degrades kininogen both in an 
isolated system  and  in  complex mixtures  such  as  plasma, 
and  that  the rapid  loss of kinin  immunoreactivity reflects 
the liberation of the hormone by SCP. 
SCP  Does  Not  Activate  Purified Ptasma  Prekallikrein, 
Under physiological conditions, the kinin release from kin- 
inogens is mediated by activated plasma kallikrein. Due to a 
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Figure  6.  Time course of prekallikrein activation by various protein- 
ases. Plasma prekallikrein was incubated for 1 h with factor Xlla in a mo- 
lar ratio of 100:1  ([~) or with SCP in molar ratio of 100:1  (&) and 10:1 
(O), At the indicated time points aliquots of the reaction mixtures were 
removed, and their amidolytic activity tested by a chromogenic substrate 
assay (H-D-Pro-Phe-Arg-pNA). For control, prekallikrein incubated in 
the absence ofSCP (~), or SCP alone (V) were tested. 
reciprocal  activation  factor  XII  converts  the  zymogen, 
prekallikrein,  to  the  active  enzyme, o~-kallikrein.  Hence, 
activation of plasma  prekallikrein by SCP  may explain  at 
least  in part the observed release of kinins from H-kinino- 
gen  (see  above).  To test this  possibility, prekallikrein iso- 
lated from human plasma was incubated with purified SCP, 
and  followed by  SDS-PAGE  demonstrating  that  prekal- 
likrein was rapidly processed by the streptococcal enzyme 
(data  not  shown).  The  resultant  cleavage  products  were 
tested for their amidolytic activity in  chromogenic assays 
using the p-nitroanilide derivative of  the tripeptide, H-D-Pro- 
Phe-Arg.  Prekallikrein  cleavage  products  generated  by 
varying  concentrations  of SCP  did  not  reveal significant 
amidolytic activity (Fig.  6);  likewise prekallikrein or SCP 
alone had no activity. In contrast prekallikrein activation by 
factor XIIa resulted in the progressive activation of the zy- 
mogen. Because SCP is unable to activate prekallikrein un- 
der the conditions of our experiment, we conclude that the 
bacterial  enzyme  is  likely  to  act  directly  on  kininogen 
present  in  human  plasma  without  prior  activation  of a 
physiological kininogenase. This notion is supported by the 
observation that kininogen degradation products are formed 
by SCP that do not occur in the kallikrein-mediated pro- 
cessing cascade. 
SCP Generates Kinins from Plasma Kininogens.  Our  pro- 
teolysis experiments demonstrated  that  biologically active 
kinins are released from H-kininogen by SCP in a purified 
system. We therefore asked the question whether SCP may 
liberate kinins from kininogens also in a complex environ- 
ment such as the plasma.  To this end we incubated human 
plasma with purified SCP for 2 h and tested aliquots of the 
reaction mixture after varying time periods. A competitive 
ELISA was employed and Fig. 7 demonstrates that SCP re- 
lease kinins in a time-dependent manner. After 120 min of 
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Figure 7.  Kinin generation by SCP in plasma  followed by ELISA. Hu- 
man plasma (100 txl) was incubated with 3.2 txg of SCP (IN), aliquots of 
the reaction mixture were removed at the time points indicated, and as- 
sayed for their kinin concentration by a competitive ELISA. For control 
plasma was incubated under  identical conditions except that SCP  was 
omitted  (n).  Note that the lower detection limit for bradykinin is ap- 
proximately 10  7 mol/l of plasma. 
incubation, the kinin concentration of samples had leveled 
off at  2.8  #xM  which  ahnost  approaches  the  theoretically 
releasable concentration of bradykinin in human plasma of 
3.5  txM.  Thus,  approximately 0.9  txM  H-kininogen  and 
2.6 IxM L-kininogen are present in human plasma (28). No 
release of kinins was  found  in  controls where  plasma was 
incubated  without  SCP.  These  results  demonstrate  that 
SCP-induced cleavage of kininogen in plasma is combined 
with the release of kinins. 
SCP Cleaves Kininogens In  Vivo.  To  test  whether  SCP 
also processes kininogens in vivo, we injected purified SCP 
into  the  peritoneal  cavity of mice.  Two  types  of experi- 
ments  were performed.  In the  first set of experiments, le- 
thal doses of SCP  (0.5  mg per animal) were  administrated 
intraperitoneally,  and  plasma  samples  from  these  animals 
were  taken  60  min,  150  rain,  and 300  min  after injection 
(Fig. 8  A).  For control, 0.5  Ixg SCP  that had been inacti- 
vated  by the  specific inhibitor  Z-Leu-Val-Gly-CHN  2  (4) 
was injected i.p. into mice, and plasma samples were with- 
drawn after 300 rain. In a second set of experiments, vary- 
ing amounts  of SCP  (0.1-0.5  mg)  were  injected i.p.,  and 
plasma samples were  taken  300  min  thereafter  (Fig.  8  /3). 
Kininogen degradation in plasma was detected by Western 
blotting, using antibodies to bradykinin. Three immunore- 
active band of 66, 80, and  110-kD were detected in plasma 
of mice that had been treated with vehicle only; the upper 
110-kD  band  and  the  lower 66-kD  band  correspond  to 
H-  and  L-kininogen, respectively. The  intermediate band 
of 80  kD  may  correspond  to  a  modified form  of mouse 
L-kininogen, ir-kininogen, that has recently been described 
in mouse fibroblasts (29).  Plasma of mice that had been in- 
jected  with  SCP  60  nfin  prior  to  bleeding  completely 
lacked the immunoreactive H-kininogen band of 110  kD. 
Figure 8.  Cleavage  of plasma kininogens by SCP in vivo. (A) Mice 
were injected i.p. with  0.5  mg of purified SCP. Plasma samples were 
drawn from the animals after 60 rain (lane 2), 150 rain (lane 3), and 300 
rain (lane 4). Alternatively, 0.5 mg SCP mixed with 0.2 mg Z-Leu-Val- 
Gly-CHN  2 was injected, and a plasma sample from this mouse was taken 
300 rain after injection (lane 5).  For control, plasma from a mouse in- 
jected with PBS alone was used (lane 1). I  Fxl of each sample was sepa- 
rated by SDS-PAGE, transferred to  nitrocellulose and  inmmnostained 
with  antibodies to  bradykinin  (ot-BK). The  relative positions of the 
marker proteins are given to the left, and those of the mouse plasma kinin- 
ogens are indicated to the fight. (/3) Mice were injected (i.p.) with PBS 
alone (lane 1), 0.1 nag of SCP (lane 2), 0.2 mg of SCP (lane 3), 0.3 mg of 
SCP (lane 4), 0.4 mg of SCP (lane 5), or 0.5 mg of SCP (lane 6). Plasma 
samples were taken 300 rain after injection. 
After 150 rain most of the plasma kininogens had been de- 
graded,  and  after  300  min  no  kininogen  fragments  were 
detectable.  By  contrast  the  majority of plasma kininogens 
from  animals  that  had  been  injected  with  the  enzyme- 
inhibitor complex remained intact. 
A  dose-dependent  effect  of SCP  on  plasma  kininogen 
degradation was found when we injected increasing anaounts 
of SCP (Fig. 8  B). Even at lowest enzyme amounts (0.1  and 
0.2  nag)  a  significant  fraction  of plasma  kininogens  was 
found  to  be  degraded.  At high  SCP  amounts  (/>0.4  nag) 
hardly any  kinin-containing kininogen  fragments  or frag- 
ments  thereof  were  detectable.  From  semi-quantitative 
Western blot analyses we judged the plasma concentration 
of SCP to be in the range of 3-25  Ixg/ml of plasma depen- 
dent  on  the  anaount  of  injected  enzyme  and  the  time 
elapsed after injection (Table 1). 
Alternatively, living streptococci of strain AP  1 were in- 
jected i.p..  Plasma samples were drawn then from the ani- 
mals 8 h  after injection, and analyzed by SDS-PAGE (Fig. 9). 
Table 1.  Quant!fication of SCP in Mouse Plasma 
Amount of SCP  Time of the  Plasma 
administered (i.p.)  administration  concentration* 
mg  min  lzglml 
0.5  6O  12 
0.5  15O  2O 
0.5  300  25 
O. 1  300  2 
0.2  3O0  12 
0.3  300  12 
0.4  300  20 
*The SCP plasma concentration  was judged from Western blots using 
purified SCP as the standard. 
670  Streptococcal Cysteine Proteinase Releases Kinim Figure 9.  Cleavage  of plasma kininogens by S, pyogenes in vivo. Mice 
were injected i.p. with 0.5 mg of purified SCP or with living S. pyogenes 
bacteria (3  ￿  l0  s cells) diluted in 0.5 ml PBS. (A) Plasma samples (1  txl 
each) from animals injected with PBS alone (lane 1), with purified SCP 
(lane 2), or with S. pyogenes bacteria (lane 3) were run on SDS-PAGE and 
stained with Coomassie Brilliant Blue. (/3) An identical replica on nitro- 
cellulose was probed with antibodies to bradykinin (r  Standard mo- 
lecular marker proteins were run simultaneously (not shown); their rela- 
tive positions are indicated on the left. The positions of mouse kininogens 
are marked. 
Coomassie Brilliant  Blue  staining  showed  no  apparent  dif- 
ference between  normal mouse plasma and plasma samples 
from mice injected with SCP or AP  1 bacteria demonstrat- 
ing that the overall protein composition  of plasma was un- 
changed  (Fig.  9  A).  In  the  corresponding  Western  blots, 
SCP  was  detected  in  the  plasma  of mice  given  0.5  mg of 
the  enzyme  i.p.,  but  not  in  the  plasma  of mice  infected 
with  AP  1  bacteria,  indicating  that  the  concentration  of 
SCP  was lower in  the latter  experimental  setting  (data not 
shown).  This observation may also explain why kininogens 
were not completely degraded in these animals (see Fig. 8  B). 
Immunoprinting  of the  plasma  samples  with  oL-BK  anti- 
bodies  revealed  that  native  H-kininogen  was  completely 
absent  from  the  plasma  of mice  treated  with  SCP  as  evi- 
denced by the kinin immunoreactivity.  Furthermore,  kinin- 
ogen  concentrations  were  considerably  though  not  com- 
pletely  reduced  in  the  plasma  of mice  infected  with  S. 
pyogenes of the AP  1 strain  (Fig.  9/3).  These findings  dem- 
onstrate  that kininogens  are also degraded  by SCP in vivo, 
most likely under the release of kinins.  For control we used 
AP  74 bacteria,  the  only strain  of S. pyogenes  that we have 
found  not  to  produce  SCP  (Cooney,  J.,  C.  Liu,  and  L. 
Bj6rck,  manuscript  in  preparation).  No  significant  decrease 
ofkininogens  was seen in plasma of mice treated  with  the 
same  protocol  as  above  except  that  AP  74  bacteria  were 
used  (not  shown),  thus  underlining  the  specific  role  for 
SCP  in  kininogen  turnover  and  kinin  release.  Together, 
these  data  demonstrate  that purified  SCP  or SCP  secreted 
by S. pyogenes,  cleaves kininogens  in vivo under the release 
of kinins. 
Discussion 
In recent years several lines of evidence have suggested a 
pathogenetic  role for extracellular microbiological  cysteine 
proteinases.  Such  enzymes  appear  to  be  involved  in  host 
colonization,  tissue invasion, evasion of host defense mech- 
anism,  and  modulation  of imnmnological  and  inflamma- 
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tory responses  (for a  review,  see  reference  30).  Moreover, 
experimental data have suggested  that a cysteine proteinase 
of Ttypanosoma  cruzi could be used as a target for immuno- 
prophylaxis (31, 32). 
SCP  was  the  first prokaryotic  cysteine  proteinase  to  be 
isolated  (2),  and in these early studies  the  enzyme attracted 
attention by its capacity to destroy the type-specific M  pro- 
tein  of S. pyogenes,  a  major virulence  determinant  of these 
bacteria  (see M  protein  review,  reference  33).  During  the 
following  decades  the  protein  chemical  and  enzymatic 
properties  of SCP  were  described  in  numerous  investiga- 
tions,  especially by Elliott and Liu and their coworkers (for 
a  review,  see reference  34).  S. pyogenes  produces  the  three 
erythrogenic  exotoxins A, B  and  C,  and  out  of these exo- 
toxin B  was shown to be identical to SCP  (3, 35).  In a cul- 
ture of S. pyogenes, SCP first appears in the growth medium 
as  an  inactive  zymogen of 40  kD  that  is transformed  into 
the  active proteinase  (28  kD)  by limited  proteolysis  or  by 
autocatalysis  under  reducing  conditions  (36).  Interestingly, 
SCP is also found in its active form within the streptococcal 
cell  (37)  suggesting  that  the  enzyme  has  also  intracellular 
functions.  This notion is supported by the finding that spe- 
cific blockage of cysteine proteinase  activity blocks S. pyo- 
genes growth  in vitro  (4)  implying that cysteine proteinases 
such  as SCP  may serve essential functions  also in prokary- 
otic  cells.  Several  observations  indicate  that  the  secreted 
form  of SCP  contributes  to  the  virulence  of S.  pyogenes. 
For example the proteinase degrades abundant  extracellular 
matrix proteins  like  fibronectin  and  vitronectin  (8),  and  it 
activates the pro-inflammatory cytokine interleukin-113  (7). 
In addition,  SCP releases biologically active fragments from 
various  surface proteins  of S. pyogenes  (9).  One  of these,  a 
fragment  of  streptococcal  CSa  peptidase,  was  found  to 
block C5a-mediated granulocyte migration (10). These and 
other findings  (38)  support  the notion  that SCP  is a  major 
virulence determinant. 
The  starting  point  for  our  present  investigation  into  a 
possible link between SCP and kininogens  was the demon- 
stration  that most strains  of S. pyogenes bind human plasma 
kininogens  specifically  and  tightly  through  their  surface- 
associated antiphagocytic M-protein  (16).  The finding  that 
kininogens  are  attached  to  the  bacterial  surface  raised  the 
question  whether  these  potent  cysteine  proteinase  inhibi- 
tors might regulate the proteolytic activity of secreted SCP. 
Unexpectedly,  our experiments demonstrated that H-kinin- 
ogen is unable  to inhibit  SCP;  the  reason for this failure is 
presently  unknown.  Rather  H-kininogen  was  a  substrate 
for SCP,  and  the  resultant  cleavage  pattern  suggested  that 
kinins  might  have  been  released  from  kininogen  by  the 
specific action of SCP, an assumption that was subsequently 
verified.  Hence SCP is an efficient kininogenase  which re- 
leases  the  pro-inflammatory  kinins  in  solution.  We  have 
not  tested  yet  whether  surface-bound  kininogens  are  also 
processed by SCP, but the fact that kinins are released from 
neutrophil-bound  kininogens by kallikreins (39)  clearly points 
to such a possibility. 
The  recruitment  of kininogens  from human  body fluids 
by M-protein  at  the  streptococcal  surface  will  lead  to  the local accumulation of the kinin precursor molecules in in- 
fected tissues.  If SCP secreted by the bacteria  cleaves these 
kininogen molecules,  a local burst of kinins will cause in- 
creased  vascular  permeability.  Such  a  sequence  of events 
would promote a flow of nutrients into the site of infection 
and at the same time enhance the spreading of the infection 
via  facilitated  extravasation.  This  hypothetical  scenario  is 
supported by the observation that SCP secretion is depen- 
dent on environmental factors such as pH (34). Notably the 
pH is low in the center of suppurative streptococcal infec- 
tions (40), and most strains of S. pyogenes produce excessive 
amounts of SCP (10-150 mg/L of growth medium) when 
grown at pH 5.5-6.0. 
In severe  cases  of sepsis,  hypovolemic hypotension is  a 
prominent and clinically important finding that is caused by 
the leakage of plasma into the extravascular space (41). The 
rapid  and  efficient  cleavage  of kininogens  to  kinins  in 
mouse plasma following the  administration  of SCP  or liv- 
ing S. pyogenes bacteria is the major finding of this study. It 
indicates that a general and massive release  of kinins could 
take  place in severe  streptococcal infections,  such as sepsis 
and streptococcal toxic shock syndrome. These  conditions 
are  characterized by raging fever,  drop  in blood pressure, 
and multiorgan failure (1, 41). In this context it is notewor- 
thy that patients with low titers of antibodies to SCP in the 
acute phase are more likely to die in severe S. pyogenes  in- 
fections (6),  and that immunization of mice with SCP gen- 
erates  partial  protection  against  S.  pyogenes  administrated 
i.p.  (5).  Furthermore,  a single dosis of a tripeptide  deriva- 
tive which blocks the  enzymatic activity of SCP  (4)  cures 
mice  given  an  otherwise  lethal  dosis  of  this  enzyme 
(Cooney, Liu, and Bj6rck, in preparation).  These and other 
data described above, underline  the significance of SCP in 
the pathogenesis of streptococcal infections. The major and 
novel aspect of this work is that we have identified a poten- 
tial downstream effector of SCP, i.e.,  kinins.  Recruitment 
of host proteins and exploitations  of their intrinsic  proper- 
ties by the parasite is a phenomenon that is probably com- 
mon to many pathogenic bacteria.  Our results also indicate 
that  SCP  and/or  kinins  could  be  therapeutical  targets  in 
hyperacute  and  severe  S.  pyogenes  infections  where  treat- 
ment with antibiotics  alone is insufficient.  Specific inhibi- 
tion  of these potential  mediators  of shock could interrupt 
an otherwise fatal pathologic sequence. 
We wish to thank our colleagues Drs. W. Machleidt  and I. Assfalg-Machleidt (Ludwig Maximilian Univer- 
sity, Munich) for experimental  help with the inhibitor  assays; A. Maidhofand B. Welsch (Johannes Guten- 
berg University,  Mainz) for providing antisera; A. Horstmeyer (Mainz) for experimental  help with the fura 
assay, U. Quitterer (University of Wiirzburg)  and P. Akesson (Lund University) for their critical comments 
on the manuscript, and B. J6nnson (Lund University) for preparing the figures. 
This work was supported  in part by The Swedish Medical  Research Council (grant 7480),  the Deutsche 
Forschungsgemeinschaft  (Mu598/5.2),  the  Fonds  der  Chemischen  Industrie  (to  W.  Mtiller-Esterl),  the 
Foundations  of Kock and Osterlund,  and High Tech Receptor AB. 
Address correspondence  to Heiko Herwald,  Department of Cell and Molecular Biology, Section for Molec- 
ular Pathogenesis, Lund University,  P.O. Box 94, S-221 00 Lund, Sweden. 
Received  for publication  12 March  I996 and in revised  form 28 May  1996. 
References 
1. Nowak,  R.  1994.  Flesh-eating  bacteria:  not  new,  but  still 
worrisome. Science (Wash. DC). 264:1665. 
2.  Elliott,  S.D.  1945. A proteolytic enzyme produced by group 
A streptococci with special reference to its effect on the type- 
specific M antigen.J. Exp.  Med. 81:573-592. 
3.  Gerlach,  D., H. Knoll, W. KShler, J.H.  Ozegowski, and V. 
Hrihalova.  1983.  Isolation and  characterization  of erythro- 
genic  toxins.  V.  Communication:  identity  of erythrogenic 
toxin type B and streptococcal proteinase  precursor. ZentralbL 
Bakteriol. Mikrobiol, Hyg. A. 255:221-233. 
4.  Bj/Srck, L., P. Akesson,  M. Bohus, J. Trojnar, M. Abraham- 
son,  I.  Olafsson,  and  A.  Grubb.  1989.  Bacterial  growth 
blocked by a synthetic peptide based on the structure of a hu- 
man proteinase  inhibitor.  Nature (Loud.). 337:385-386. 
5. Kapur, V., J.T. Maffei, R.S. Greer,  L.L. Li, G.J. Adams,  and 
J.M.  Musser.  1994.  Vaccination with streptococcal extracel- 
lular cysteine protease  (interleukin-1  beta convertase)  protects 
mice  against  challenge  with  heterologous group A  strepto- 
cocci. Microb. Pathol. 16:443-450. 
6.  Holm, S.E., A. Norrby, A.-M. Bergholm, and M. Norgren. 
1992. Aspects of patogenesis  of serious group A streptococcal 
infections  in Sweden 1988-1989.J. Infect, Dis. 166:31-37. 
7.  Kapur,  V.,  M.W.  Majesky,  L.L.  Li,  R.A.  Black,  and J.M. 
Musser.  1993. Cleavage  ofinterleukin 1 beta (IL-I beta) pre- 
cursor to produce active IL-1 beta by a conserved extracellu- 
lar  cysteine  protease  from  Streptococcus pyogenes. Proc. Natl. 
Acad. Sci. USA, 90:7676-7680. 
8.  Kapur, V,, S. Topouzis, M.W. Majesky, L.L. Li, M.R. Ham- 
rick,  R.J. Hamill, J.M.  Patti,  and J.M. Musser.  1993. A con- 
served  Streptococcus pyogenes extracellular  cysteine  protease 
cleaves human fibronectin and degrades  vitronectin.  Microb. 
Pathol. 15:327-346. 
9.  Berge, A., and L. Bj6rck.  1995.  Streptococcal cysteine  pro- 
teinase  releases biologically  active  fragments  of streptococcal 
surface proteins.J. Biol. Chem. 270:9862-9867. 
10, Wexler,  D.E.,  D,E.  Chenoweth,  and  P.P.  Cleary.  1985. 
672  Streptococcal Cysteine Proteinase Releases Kinins Mechanism of action of the group A streptococcal CSa inac- 
tivator. Proc. Natl. Acad.  Sci.  USA.  82:8144-8148. 
11. Wolf,  B.B.,  C.A.  Gibson,  V.  Kapur,  I.M.  Hussaini, J.M. 
Musser, and S.L. Gonias. 1994.  Proteolytically active strepto- 
coccal pyrogenic exotoxin B  cleaves monocytic cell uroki- 
nase receptor and releases  an active fragment of the receptor 
from the cell surface.J. Biol.  Chem. 269:30682-30687. 
12. Poon-King,  R.,  J.  Bannan,  A.  Viteri,  G.  Cu,  and  J.B. 
Zabriskie.  1993.  Identification of an  extracellular plasmin 
binding  protein  from  nephritogenic  streptococci. J.  Exp. 
Mecl. 178:759-763. 
13. Hall, J.M. 1992. Bradykinin receptors: pharmacological prop- 
erties and biological roles. Pharmac. Ther.  56:131-190. 
14. Kerbiriou, D.M., and J.H.  Griffin. 1979.  Human High Mo- 
lecular Weight Kininogen.J. Biol.  Chem. 254:12020-12027. 
15.  Miiller-Esterl, W.,  G. Rauth,  F.  Lottspeich, J.  Kellermann, 
and A. Henschen.  1985.  Limited proteolysis of human low- 
molecular-mass kininogen by tissue  kallikrein. Isolation and 
characterization of the heavy and the light chains. Eur. J. Bio- 
chem.  149:15-22. 
16. Ben  Nasr,  A.B.,  H.  Herwald,  W.  Miiller-Esterl, and  L. 
Bjrrck. 1995.  Human kininogens interact with M  protein, a 
bacterial surface protein and virulence determinant. Biochem. 
J. 305:173-180. 
17. Salvesen, G., C. Parkes, M. Abrahamson, A. Grubb, and A.J. 
Barrett. 1986.  Human low-Mr kininogen contains three cop- 
ies of a cystatin sequence that are divergent in structure and 
in inhibitory activity for cysteine proteinases. Biochem. J. 234: 
429-434. 
18. Hasan,  A.A.,  D.B.  Cines,  J.  Zhang,  and  A.H.  Schmaier. 
1994.  The carboxyl terminus ofbradykinin and amino termi- 
nus of the light chain of kininogens comprise an endothelial 
cell binding domain.J. Biol.  Chem. 269:31822-31830. 
19. Kaufmann, J., M.  Haasemann, S. Modrow, and W. Miiller- 
Esterl. 1993. Structural dissection of the multidomain kinino- 
gens. Fine mapping of the target epitopes of antibodies inter- 
fering with  their functional properties. J.  Biol.  Chem.  268: 
9079-9091. 
20. Miiller-Esterl, W., D. Johnson, G. Salvesen, and A.A. Barrett. 
1988. Human kininogens. Methods Enzymol.  163:240-256. 
21.  Herwald,  H.,  A.H.K.  Hasan,  J.  Godovac-Zimmermann, 
A.H. Schmaier, and W. Miiller-Esterl. 1995.  Identification of 
an endothelial cell binding site on kininogen domain D3. J. 
Biol.  Chem. 270:14634-14642. 
22.  Laemmli, U.K.  1970.  Cleavage of structural proteins during 
the assembly of the head of bacteriophage T4. Nature (Dnd.). 
227:680-685. 
23. Khyse-Andersen, J.  1984.  Electroblotting of multiple gels: a 
simple apparatus without buffer tank for rapid transfer of pro- 
teins from polyacrylamide to nitrocellulose. J.  Biochem.  Bio- 
phys. Methods.  10:203-209. 
24.  Towbin,  H.,  T.  Staehelin,  and J.  Gordon.  1979.  Electro- 
phoretic transfer of proteins from polyacrylamide gels to ni- 
trocellulose sheets:  procedure  and  some  applications. Pro& 
Natl. Acad.  Sci.  USA.  76:4350-4354. 
25. Quitterer, U., C. Schr/Sder, W. Miiller-Esterl, and H. Rehm. 
1995.  Effects ofbradykinin and endothelin-I on the calcium 
homeostasis of mammalian  cells. J.  Biol.  Chem.  270:1992- 
1999. 
26. Scott, C.F., E.J. Whitaker, B.F. Hammond, and R.W. Col- 
man.  1993.  urification and characterization of a potent 70- 
kDa thiol lysyl-proteinase (Lys-gingivain) from Porphyromonas 
gingivalis  that  cleaves  kininogens  and  fibrinogen. J.  Bid. 
Chem. 268:7935-7942. 
27. Vogel, R., I. Assfalg Machleidt, A. Esterl, W. Machleidt, and 
W.  Miiller-Esterl. 1988.  Proteinase-sensitive regions in the 
heavy chain of low molecular weight kininogen map to the 
inter-domainjunctions.J. Biol.  Chem. 263:12661-12668. 
28. Miiller-Esterl,  W.  1987.  Novel  functions  of  kininogens. 
Semin.  Thromb.  Hemostas.  13:115-126. 
29.  Takano,  M.,  K. Yokoyama, K. Yayama, and H.  Okamoto. 
1995.  Murine fibroblasts synthesize and secrete kininogen in 
response to cyclic-AMP, prostaglandin E2 and tumor necrosis 
factor. Biochim.  Biophys.  Acta.  1265:189-195. 
30.  Travis, J., J.  potempa,  and  H.  Maeda.  1995.  Are bacterial 
proteinases pathogenic factors?  Trends Microbiol. 3:405--407. 
31. Eakin, A.E., M.E. McGrath, J.H. McKerrow, R.J. Fletterick, 
and  C.S.  Craik.  1993.  Production  of crystallizable cruzain, 
the major cysteine protease from  Trypanosoma  cruzi. J.  Biol. 
Chem.  268:6115-6118. 
32.  Martinez, J.,  O.  Campetella, A.C.  Frasch, and J.J.  Cazzulo. 
1991.  The major cysteine proteinase (cruzipain) from Trypa- 
nosoma cruzi is antigenic in human infections. Infect. Immunot. 
59:4275-4277. 
33. Fischetti, V.A. 1989.  Streptococcal M protein: molecular de- 
sign and biological behavior. Clin. Microbiol. Rev. 2:285-314. 
34.  Liu, T.-Y., and S.D. Elliott. 1971. The Enzymes Vol. 3. P.D. 
Boyer, editor. Academic Press, New York. 609-639. 
35. Hauser,  A.R.,  and  P.M.  Schlievert.  1990.  Nucleotide  se- 
quence of the streptococcal pyrogenic exotoxin type B gene 
and relationship between the toxin and the streptococcal pro- 
teinase precursor.J. Bacteriol. 172:4536-4542. 
36. Liu, T.-Y., and S.D. Elliott. 1965.  Streptococcal proteinase. 
the zymogen to enzyme transformation. J.  Biol.  Chem.  240: 
1138-1142. 
37. Lo, S.S.,  S.M. Liang, and T.Y. Liu. 1984.  Intracellular form 
of streptococcal proteinase: a clue to a novel mechanism of 
secretion. Anal.  Biochem.  136:89-92. 
38.  Kellner, A.,  and  T.  Robertson.  1954.  Myocardial necrosis 
produced  in  animals  by  means  of crystalline streptococcal 
proteinase.J. Exp. Med. 99:495-504. 
39.  Henderson,  L.M.,  C.D.  Figueroa,  W.  Miiller-Esterl, and 
K.D. Bhoola. 1994. Assembly of contact-phase factors on the 
surface of the human neutrophil membrane. Blood. 84:474-482. 
40. Rentzsch, G., and J. Wilke. 1970.  Measurements of pH val- 
ues  in  vitro and in vivo in  chronic  tonsillitis. Z.  Laryngol. 
Rhinol.  Otol. 49:391-397. 
41. Pamllo, J.E.  1993.  Pathogenetic mechanisms of septic shock. 
N.  Engl.J.  Med. 328:1471-1477. 
673  Herwald et al. 